These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32800294)

  • 1. Digoxin Use in Cardiac Amyloidosis.
    Donnelly JP; Sperry BW; Gabrovsek A; Ikram A; Tang WHW; Estep J; Hanna M
    Am J Cardiol; 2020 Oct; 133():134-138. PubMed ID: 32800294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
    Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
    PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
    Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
    Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
    Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
    Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
    [No Abstract]   [Full Text] [Related]  

  • 5. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?
    Muchtar E; Gertz MA; Kumar SK; Lin G; Boilson B; Clavell A; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Dingli D; Rajkumar SV; Dispenzieri A; Grogan M
    Amyloid; 2018 Jun; 25(2):86-92. PubMed ID: 29529877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural History and Disease Progression of Early Cardiac Amyloidosis Evaluated by Echocardiography.
    Itzhaki Ben Zadok O; Eisen A; Shapira Y; Monakier D; Iakobishvili Z; Schwartzenberg S; Abelow A; Ofek H; Kazum S; Ben-Avraham B; Hamdan A; Bental T; Sagie A; Kornowski R; Vaturi M
    Am J Cardiol; 2020 Oct; 133():126-133. PubMed ID: 32811652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
    Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
    ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Porcari A; Rossi M; Cappelli F; Canepa M; Musumeci B; Cipriani A; Tini G; Barbati G; Varrà GG; Morelli C; Fumagalli C; Zampieri M; Argirò A; Vianello PF; Sessarego E; Russo D; Sinigiani G; De Michieli L; Di Bella G; Autore C; Perfetto F; Rapezzi C; Sinagra G; Merlo M
    Eur J Heart Fail; 2022 Jul; 24(7):1227-1236. PubMed ID: 35509181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis.
    Binder C; Duca F; Stelzer PD; Nitsche C; Rettl R; Aschauer S; Kammerlander AA; Binder T; Agis H; Kain R; Hengstenberg C; Mascherbauer J; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2019 May; 20(5):512-524. PubMed ID: 30649240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review.
    Bukhari S; Khan SZ; Bashir Z
    J Card Fail; 2023 Jan; 29(1):76-86. PubMed ID: 36122817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of digoxin for heart failure and atrial fibrillation in elderly patients.
    Cheng JW; Rybak I
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):419-27. PubMed ID: 21335295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digoxin prescribing for heart failure in elderly residents of long-term care facilities.
    Misiaszek B; Heckman GA; Merali F; Turpie ID; Patterson CJ; Flett N; McKelvie RS
    Can J Cardiol; 2005 Mar; 21(3):281-6. PubMed ID: 15776118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
    Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
    Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
    Debonnaire P; Claeys M; De Smet M; Trenson S; Lycke M; Demeester C; Van Droogenbroeck J; De Vriese AS; Verhoeven K; Vantomme N; Van Meirhaeghe J; Willandt B; Lambert M; de Paepe P; Delanote J; De Geeter F; Tavernier R
    Acta Cardiol; 2022 Nov; 77(9):791-804. PubMed ID: 34565298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin.
    Eichhorn EJ; Gheorghiade M
    Prog Cardiovasc Dis; 2002; 44(4):251-66. PubMed ID: 12007081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between digoxin and dronedarone in the PALLAS trial.
    Hohnloser SH; Halperin JL; Camm AJ; Gao P; Radzik D; Connolly SJ;
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1019-25. PubMed ID: 25378467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When, and when not, to use digoxin in the elderly.
    Gosselink AT; van Veldhuisen DJ; Crijns HJ
    Drugs Aging; 1997 Jun; 10(6):411-20. PubMed ID: 9205847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Do we use digitalis properly in the management of elderly patients suffering from the signs of chronic heart failure?].
    Erdei F; Vendrey R; Dani G; Kovács E; Márk L; Katona A
    Orv Hetil; 2006 Oct; 147(41):1993-6. PubMed ID: 17120690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Digoxin on Mortality in Patients With Atrial Fibrillation Stratified by Heart Failure: Findings From Gulf Survey of Atrial Fibrillation Events in the Middle East.
    Al-Zakwani I; Panduranga P; Zubaid M; Sulaiman K; Rashed WA; Alsheikh-Ali AA; AlMahmeed W; Shehab A; Al Qudaimi A; Asaad N; Amin H
    J Cardiovasc Pharmacol Ther; 2016 May; 21(3):273-9. PubMed ID: 26341119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.